Beyond Skin Deep: The Role of Systemic Therapies in Psoriasis & Melasma

Abstract

Psoriasis and melasma are distinct dermatologic conditions that extend beyond the superficial layers, often requiring systemic approaches due to their complex pathophysiology and profound impact on patient quality of life. This article comprehensively reviews the current understanding of these disorders, emphasizing the clinical rationale for systemic therapies. We discuss epidemiological trends, underlying mechanisms, risk stratification, clinical manifestations, diagnostic strategies, therapeutic interventions, recent advances, and guideline recommendations, with a focus on evidence-based, mechanism-driven, and practical insights for healthcare professionals.

Introduction

Both psoriasis and melasma present unique therapeutic challenges that transcend basic topical management, compelling clinicians to consider systemic interventions in moderate to severe or refractory cases. Psoriasis, a chronic immune-mediated disease, and melasma, a pigmentary disorder with multifactorial etiology, can greatly influence psychosocial well-being and physical health. Understanding their complex pathogenesis and the evolving landscape of systemic therapies is crucial for optimal patient outcomes, particularly as new evidence reshapes management paradigms.

Epidemiology / Disease Burden

Psoriasis affects 1–3% of the global population, with marked geographic and ethnic variability. It is associated with metabolic syndrome, cardiovascular disease, and psychological comorbidities, amplifying its societal impact. Melasma, while not life-threatening, is highly prevalent among women of reproductive age, especially in darker skin phototypes and populations exposed to high ultraviolet (UV) radiation. The chronic and relapsing nature of both conditions imposes significant healthcare costs, reduced productivity, and diminished quality of life, highlighting the need for effective, durable treatment strategies.

Pathophysiology

Psoriasis is primarily driven by dysregulated immune responses, particularly involving T-helper 17 (Th17) cells, interleukin (IL)-23/IL-17 axis, and aberrant keratinocyte proliferation. Genetic susceptibility, environmental triggers, and systemic inflammation contribute to disease expression and progression. Melasma's pathogenesis is multifactorial, involving genetic predisposition, hormonal influences (such as pregnancy and oral contraceptives), UV exposure, and cutaneous inflammation. Recent research underscores the roles of dermal fibroblasts, vascular factors, and oxidative stress in persistent hyperpigmentation, supporting the rationale for systemic interventions in select cases.

Risk Factors

Established risk factors for psoriasis include family history, obesity, smoking, alcohol use, certain medications (e.g., beta-blockers, lithium), infections, and chronic stress. For melasma, risk factors encompass female sex, Fitzpatrick skin types III–VI, hormonal fluctuations, phototoxic drugs, and chronic sun exposure. Both diseases may be exacerbated by systemic factors, reinforcing the importance of holistic risk assessment in management planning.

Clinical Features

Psoriasis manifests most commonly as well-demarcated, erythematous plaques with silvery scales, often on extensor surfaces, scalp, and sacral region. Subtypes include guttate, pustular, erythrodermic, and inverse psoriasis. Extracutaneous involvement, notably psoriatic arthritis, occurs in up to 30% of patients. Melasma is characterized by symmetric, hyperpigmented macules and patches, predominantly on sun-exposed facial areas. The disease course is chronic and relapsing, with significant cosmetic and psychological implications.

Diagnosis

Diagnosis of psoriasis is primarily clinical, supported by history and examination. Biopsy may be warranted for atypical or refractory cases. Severity assessment tools such as the Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) guide therapeutic decisions. Melasma is diagnosed based on clinical appearance, Wood’s lamp examination, and exclusion of other causes of facial dyspigmentation. Histopathology may reveal increased melanin in the epidermis and/or dermis, with solar elastosis and dermal melanophages.

Treatment & Management

First-line therapy for mild to moderate psoriasis and melasma typically includes topical agents—corticosteroids, vitamin D analogs, calcineurin inhibitors (for psoriasis), and hydroquinone, azelaic acid, or triple combinations (for melasma). However, moderate to severe disease or poor response necessitates systemic approaches. Systemic treatments for psoriasis comprise conventional agents (methotrexate, cyclosporine, acitretin), biologics targeting TNF-α, IL-12/23, IL-17, and IL-23, and small molecules (apremilast). Melasma systemic therapies—though less established—include tranexamic acid, oral antioxidants, and emerging agents targeting melanogenesis and vascular factors. Individualized therapy considers comorbidities, disease severity, and patient preferences.

Recent Advances / Emerging Therapies

The therapeutic arsenal for psoriasis has expanded with newer biologics demonstrating superior efficacy and safety, including IL-23 inhibitors (guselkumab, tildrakizumab, risankizumab) and IL-17 inhibitors (secukinumab, ixekizumab, brodalumab). These agents offer rapid disease control, sustained remission, and improved quality of life. Oral small molecules such as TYK2 inhibitors are under active investigation. In melasma, oral tranexamic acid has shown promise in recalcitrant cases, potentially through antifibrinolytic and antiangiogenic mechanisms. Systemic antioxidants and novel agents targeting melanocyte-keratinocyte interactions represent future therapeutic avenues, although further large-scale trials are warranted.

Guideline Recommendations

International guidelines advocate systemic therapy for moderate to severe psoriasis, especially when topical treatments fail, or quality of life is significantly impaired. Selection of biologics or traditional systemic agents is tailored based on efficacy, safety profile, comorbid conditions, and patient preferences. For melasma, guidelines emphasize photoprotection, topical therapy, and cautious use of systemic agents such as tranexamic acid in refractory cases, with close monitoring for adverse effects. Multidisciplinary management and patient education are integral to optimizing outcomes.

Conclusion

The management of psoriasis and melasma increasingly necessitates a systemic perspective, reflecting advances in understanding their complex pathophysiology and the limitations of topical therapy alone. Systemic treatments, particularly biologics for psoriasis and select oral agents for melasma, offer hope for improved disease control, functional outcomes, and quality of life. Continued research into personalized, mechanism-based interventions and long-term safety will further shape the therapeutic landscape, bridging the gap between skin manifestations and systemic health.